Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFor most people, headaches on Mounjaro last between a few hours and two to three days, typically appearing after a new injection or a dose step-up and easing on their own. They sit in the 'common but manageable' category documented in the NHS tirzepatide medicines page, and for the majority they become less frequent as the body adjusts over the first several weeks. Mounjaro (tirzepatide) is a prescription-only medicine, so its side effects (including headache) are one of the things a GPhC-registered prescriber will walk through with you at consultation, because the pattern matters clinically.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The pattern our prescribers hear about most weeks runs like this: injection day or the day after, a low-to-moderate headache settles in, sometimes accompanied by mild nausea or fatigue. It tends to peak within 24 to 48 hours and then gradually fade. This timing is not coincidental. Tirzepatide slows gastric emptying and acts on appetite-regulating centres in the brain, and both effects can nudge blood sugar and fluid balance in ways that trigger headache, particularly if eating and drinking less than usual has already started.
The first injection at 2.5 mg is a tolerability dose: its job is to settle your system gently rather than deliver the full therapeutic effect. Even so, some people feel a headache after it. After a dose increase (say, moving from 5 mg to 7.5 mg) a new adjustment phase begins and headache may return briefly even for people who thought they were past it. That is normal. It is also why the full side-effect picture for Mounjaro is worth understanding before you start, not just when something happens.
One practical check you can do right now: think back over the 24 hours before the headache arrived and estimate how much plain water you drank. Many people find the number is lower than usual, often because nausea made eating and drinking unappealing. Jenni Murray wrote about her Mounjaro side effects, and dehydration-related headache was among the experiences she described as catching her off guard. Mild dehydration is one of the most common and most correctable headache triggers on GLP-1 treatment.
There is no single answer, because duration varies by person and context. Broadly, the evidence-based picture looks like this. A headache linked mainly to dehydration or reduced food intake often settles within a few hours once fluids are restored. A headache that is part of the body's general adjustment to tirzepatide (as described on the NHS medicines page for tirzepatide) typically lasts one to three days. A headache that coincides with significant nausea or vomiting may persist a little longer, because the dehydration cycle is harder to break when keeping fluids down is itself difficult.
After two to four weeks at a stable dose, headaches tend to tail off for most people. If they have not settled after six weeks at the same dose, that is worth flagging to your prescriber rather than waiting it out indefinitely. The broader timeline for how long Mounjaro side effects last covers the other common early symptoms alongside headache, which can help you calibrate whether your experience is running to type.
Paracetamol at standard doses is widely used for this kind of headache. Your prescriber or pharmacist can confirm what is appropriate for you personally, especially if you take other medicines.
Most Mounjaro headaches are dull, manageable and short-lived. The ones that need prompt attention have a different character. Seek medical advice the same day (or call 999 in an emergency) if you experience: a headache that is severe or sudden-onset ('thunderclap'), headache with visual disturbance, confusion, weakness or facial drooping, or headache arriving alongside severe and persistent abdominal pain that reaches towards your back. The last combination, in particular, may indicate pancreatitis, which the MHRA Drug Safety Updates identified as an infrequent but serious effect of GLP-1 medicines in a January 2026 communication. That kind of pain is very different from an ordinary headache, but it is worth knowing what to listen for.
If you experience any side effect you are not sure about, the MHRA Yellow Card scheme lets you report it directly, which contributes to ongoing medicine safety monitoring in the UK. You can also contact your prescriber, at nume, our aftercare team is available seven days a week.
It is easy to read a headache as a sign something has gone wrong. Usually it is a sign something is changing. Tirzepatide is reshaping how your body responds to food and hunger signals; the adjustment period is real, and headache is one of its more benign expressions. The deeper look at headache as a Mounjaro side effect explores the mechanisms in more detail if that is useful.
Other side effects (diarrhoea and hair thinning among them) follow a similar adjustment arc, which is worth understanding if you notice more than one thing at once. If the headaches are persistent enough to make you question whether to continue, that conversation belongs with your prescriber. Stopping, reducing the dose or adjusting the titration schedule are all clinical decisions, and the right one depends on your full picture. The overview of Mounjaro as a treatment covers eligibility, how it works, and what the clinical programme found, if you want the broader context before that conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.